Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes

Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes Results From the Finnish Diabetes Prevention Study Christian Herder 1 , Markku Peltonen 2 , Wolfgang Koenig 3 , Ilka Kräft 1 , Sylvia Müller-Scholze 1 , Stephan Martin 1 , Timo Lakka 4 , Pirjo Ilanne-Parikka 5 , Joh...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 55; no. 8; pp. 2340 - 2346
Main Authors Christian Herder, Markku Peltonen, Wolfgang Koenig, Ilka Kräft, Sylvia Müller-Scholze, Stephan Martin, Timo Lakka, Pirjo Ilanne-Parikka, Johan G. Eriksson, Helena Hämäläinen, Sirkka Keinänen-Kiukaanniemi, Timo T. Valle, Matti Uusitupa, Jaana Lindström, Hubert Kolb, Jaakko Tuomilehto
Format Journal Article
LanguageEnglish
Published American Diabetes Association 01.08.2006
Online AccessGet full text
ISSN0012-1797
1939-327X
DOI10.2337/db05-1320

Cover

Loading…
Abstract Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes Results From the Finnish Diabetes Prevention Study Christian Herder 1 , Markku Peltonen 2 , Wolfgang Koenig 3 , Ilka Kräft 1 , Sylvia Müller-Scholze 1 , Stephan Martin 1 , Timo Lakka 4 , Pirjo Ilanne-Parikka 5 , Johan G. Eriksson 2 , Helena Hämäläinen 6 , Sirkka Keinänen-Kiukaanniemi 7 , Timo T. Valle 2 , Matti Uusitupa 8 , Jaana Lindström 2 , Hubert Kolb 1 , Jaakko Tuomilehto 2 9 10 and for the Finnish Diabetes Prevention Study Group 1 German Diabetes Clinic, German Diabetes Center, Leibniz Center at Heinrich Heine University Düsseldorf, Düsseldorf, Germany 2 Department of Epidemiology and Health Promotion, Diabetes and Genetic Epidemiology Unit, National Public Health Institute, Helsinki, Finland 3 Department Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany 4 Department of Physiology, University of Kuopio, Kuopio, Finland 5 Diabetes Center of the Finnish Diabetes Association and the Research Unit of Tampere University Hospital, Tampere, Finland 6 Research Department, Social Insurance Institution, Turku, Finland 7 Department of Public Health Science and General Practice, University of Oulu, Oulu, Finland 8 Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland 9 Department of Public Health, University of Helsinki, Helsinki, Finland 10 South Ostrobothnia Central Hospital, Seinäjoki, Finland Address correspondence and reprint requests to Dr. Christian Herder, German Diabetes Clinic, German Diabetes Center, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany. E-mail: christian.herder{at}ddz.uni-duesseldorf.de Abstract The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity, improving diet, and decreasing body weight, reduced the incidence of type 2 diabetes in individuals with overweight and impaired glucose tolerance by 58%. Here, we studied which immunological markers at baseline predicted subsequent type 2 diabetes and whether there are immunologically defined subsets of subjects who are more or less responsive to the protective effects of lifestyle intervention. We randomly assigned 522 participants to a control group ( n = 257) or a lifestyle intervention group ( n = 265). Immunological parameters at baseline included high-sensitivity C-reactive protein (CRP), serum amyloid A, interleukin-6, regulated on activation normal T-cell expressed and secreted (RANTES), macrophage migration inhibitory factor (MIF), and soluble intercellular adhesion molecule. In the control group, CRP was the best immunological predictor for progression to overt type 2 diabetes. In the intervention group, progression to type 2 diabetes was significantly higher in subjects with the highest RANTES concentrations and was lower in subjects with the highest MIF levels. Ratios of RANTES to MIF in the upper tertile were highly predictive of incident type 2 diabetes in the intervention group ( P = 0.006), whereas the association was less pronounced in the control group ( P = 0.088). Thus, systemic concentrations of immune mediators appear to be associated with the progression to type 2 diabetes and the prevention of type 2 diabetes by lifestyle changes. CRP, C-reactive protein DPS, Diabetes Prevention Study HOMA, homeostasis model assessment IGT, impaired glucose tolerance IL, interleukin KORA, Cooperative Health Research in the Region of Augsburg (Kooperative Gesundheitsforschung in der Region Augsburg) MIF, macrophage migration inhibitory factor OGTT, oral glucose tolerance test RANTES, regulated on activation, normal T-cell expressed and secreted SAA, serum amyloid A sICAM, soluble intercellular adhesion molecule Footnotes The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Accepted May 15, 2006. Received October 11, 2005. DIABETES
AbstractList Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes Results From the Finnish Diabetes Prevention Study Christian Herder 1 , Markku Peltonen 2 , Wolfgang Koenig 3 , Ilka Kräft 1 , Sylvia Müller-Scholze 1 , Stephan Martin 1 , Timo Lakka 4 , Pirjo Ilanne-Parikka 5 , Johan G. Eriksson 2 , Helena Hämäläinen 6 , Sirkka Keinänen-Kiukaanniemi 7 , Timo T. Valle 2 , Matti Uusitupa 8 , Jaana Lindström 2 , Hubert Kolb 1 , Jaakko Tuomilehto 2 9 10 and for the Finnish Diabetes Prevention Study Group 1 German Diabetes Clinic, German Diabetes Center, Leibniz Center at Heinrich Heine University Düsseldorf, Düsseldorf, Germany 2 Department of Epidemiology and Health Promotion, Diabetes and Genetic Epidemiology Unit, National Public Health Institute, Helsinki, Finland 3 Department Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany 4 Department of Physiology, University of Kuopio, Kuopio, Finland 5 Diabetes Center of the Finnish Diabetes Association and the Research Unit of Tampere University Hospital, Tampere, Finland 6 Research Department, Social Insurance Institution, Turku, Finland 7 Department of Public Health Science and General Practice, University of Oulu, Oulu, Finland 8 Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland 9 Department of Public Health, University of Helsinki, Helsinki, Finland 10 South Ostrobothnia Central Hospital, Seinäjoki, Finland Address correspondence and reprint requests to Dr. Christian Herder, German Diabetes Clinic, German Diabetes Center, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany. E-mail: christian.herder{at}ddz.uni-duesseldorf.de Abstract The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity, improving diet, and decreasing body weight, reduced the incidence of type 2 diabetes in individuals with overweight and impaired glucose tolerance by 58%. Here, we studied which immunological markers at baseline predicted subsequent type 2 diabetes and whether there are immunologically defined subsets of subjects who are more or less responsive to the protective effects of lifestyle intervention. We randomly assigned 522 participants to a control group ( n = 257) or a lifestyle intervention group ( n = 265). Immunological parameters at baseline included high-sensitivity C-reactive protein (CRP), serum amyloid A, interleukin-6, regulated on activation normal T-cell expressed and secreted (RANTES), macrophage migration inhibitory factor (MIF), and soluble intercellular adhesion molecule. In the control group, CRP was the best immunological predictor for progression to overt type 2 diabetes. In the intervention group, progression to type 2 diabetes was significantly higher in subjects with the highest RANTES concentrations and was lower in subjects with the highest MIF levels. Ratios of RANTES to MIF in the upper tertile were highly predictive of incident type 2 diabetes in the intervention group ( P = 0.006), whereas the association was less pronounced in the control group ( P = 0.088). Thus, systemic concentrations of immune mediators appear to be associated with the progression to type 2 diabetes and the prevention of type 2 diabetes by lifestyle changes. CRP, C-reactive protein DPS, Diabetes Prevention Study HOMA, homeostasis model assessment IGT, impaired glucose tolerance IL, interleukin KORA, Cooperative Health Research in the Region of Augsburg (Kooperative Gesundheitsforschung in der Region Augsburg) MIF, macrophage migration inhibitory factor OGTT, oral glucose tolerance test RANTES, regulated on activation, normal T-cell expressed and secreted SAA, serum amyloid A sICAM, soluble intercellular adhesion molecule Footnotes The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Accepted May 15, 2006. Received October 11, 2005. DIABETES
The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity, improving diet, and decreasing body weight, reduced the incidence of type 2 diabetes in individuals with overweight and impaired glucose tolerance by 58%. Here, we studied which immunological markers at baseline predicted subsequent type 2 diabetes and whether there are immunologically defined subsets of subjects who are more or less responsive to the protective effects of lifestyle intervention. We randomly assigned 522 participants to a control group (n = 257) or a lifestyle intervention group (n = 265). Immunological parameters at baseline included high-sensitivity C-reactive protein (CRP), serum amyloid A, interleukin-6, regulated on activation normal T-cell expressed and secreted (RANTES), macrophage migration inhibitory factor (MIF), and soluble intercellular adhesion molecule. In the control group, CRP was the best immunological predictor for progression to overt type 2 diabetes. In the intervention group, progression to type 2 diabetes was significantly higher in subjects with the highest RANTES concentrations and was lower in subjects with the highest MIF levels. Ratios of RANTES to MIF in the upper tertile were highly predictive of incident type 2 diabetes in the intervention group (P = 0.006), whereas the association was less pronounced in the control group (P = 0.088). Thus, systemic concentrations of immune mediators appear to be associated with the progression to type 2 diabetes and the prevention of type 2 diabetes by lifestyle changes.
Author Markku Peltonen
Jaana Lindström
Hubert Kolb
Johan G. Eriksson
Pirjo Ilanne-Parikka
Sirkka Keinänen-Kiukaanniemi
Matti Uusitupa
Christian Herder
Timo Lakka
Jaakko Tuomilehto
Wolfgang Koenig
Stephan Martin
Helena Hämäläinen
Ilka Kräft
Timo T. Valle
Sylvia Müller-Scholze
Author_xml – sequence: 1
  fullname: Christian Herder
– sequence: 2
  fullname: Markku Peltonen
– sequence: 3
  fullname: Wolfgang Koenig
– sequence: 4
  fullname: Ilka Kräft
– sequence: 5
  fullname: Sylvia Müller-Scholze
– sequence: 6
  fullname: Stephan Martin
– sequence: 7
  fullname: Timo Lakka
– sequence: 8
  fullname: Pirjo Ilanne-Parikka
– sequence: 9
  fullname: Johan G. Eriksson
– sequence: 10
  fullname: Helena Hämäläinen
– sequence: 11
  fullname: Sirkka Keinänen-Kiukaanniemi
– sequence: 12
  fullname: Timo T. Valle
– sequence: 13
  fullname: Matti Uusitupa
– sequence: 14
  fullname: Jaana Lindström
– sequence: 15
  fullname: Hubert Kolb
– sequence: 16
  fullname: Jaakko Tuomilehto
BookMark eNptkEtLxDAUhYOMOA9d-A-yFamTV5tkKeMTRhQcwV1Jm5uZyLQdmqj039syA4LIXZy7ON_lnjNFo7qpAaFzSq4Y53JuC5ImlDNyhCZUc51wJt9HaEIIZQmVWo7RNIQPQkjWzwka00xJnmk9QavXLkSofIkfq-qzBvwE1pvYtAGb2uKldxBitwW82Jh6DQH7GscN4JcWvqCOvqlx4_Cq2wFm-MabAiKEU3TszDbA2UFn6O3udrV4SJbP94-L62VSMkpJAtoZqwgnziohC0KdSMEoYlUqGFjBBGTKlIUWhRQqdZxZKQhIq_vXwQGfoYv93bJtQmjB5bvWV6btckryoZl8aCYfmum98z_e0kczBIit8dt_ics9sfHrzbdvIbeHfL9Lmuaq5wThP3CBdNE
CitedBy_id crossref_primary_10_1186_s12263_017_0580_4
crossref_primary_10_1007_s00108_007_1932_8
crossref_primary_10_1096_fj_202301357RR
crossref_primary_10_1371_journal_pone_0182359
crossref_primary_10_1038_ijo_2016_35
crossref_primary_10_1007_s00125_007_0800_3
crossref_primary_10_3904_kjim_2021_174
crossref_primary_10_1016_j_numecd_2010_01_006
crossref_primary_10_1016_S1499_2671_07_13011_2
crossref_primary_10_1038_s41430_018_0223_x
crossref_primary_10_1177_1559827607306433
crossref_primary_10_4155_fmc_10_281
crossref_primary_10_1007_s00011_010_0163_y
crossref_primary_10_1093_ajcn_nqac170
crossref_primary_10_1016_j_genm_2009_01_002
crossref_primary_10_3892_mmr_2014_2341
crossref_primary_10_1111_j_1365_2265_2008_03315_x
crossref_primary_10_4239_wjd_v15_i10_2041
crossref_primary_10_2217_bmm_2016_0359
crossref_primary_10_1016_j_neubiorev_2011_10_001
crossref_primary_10_14341_DM200418_10
crossref_primary_10_1007_s00103_009_0868_7
crossref_primary_10_3945_jn_110_132571
crossref_primary_10_1186_1755_8794_2_2
crossref_primary_10_1155_2022_8099382
crossref_primary_10_2337_dc07_0106
crossref_primary_10_3389_fgene_2022_1063519
crossref_primary_10_1053_j_ackd_2017_12_002
crossref_primary_10_1186_1475_2891_10_115
crossref_primary_10_1016_j_ijcard_2015_08_107
crossref_primary_10_1007_s11920_015_0618_5
crossref_primary_10_1155_2007_93573
crossref_primary_10_1177_0145721714521020
crossref_primary_10_1097_TP_0b013e3182a45283
crossref_primary_10_1177_1076029612467845
crossref_primary_10_1016_j_brainresbull_2012_10_002
crossref_primary_10_1007_s11428_007_0155_x
crossref_primary_10_1002_14651858_CD003054_pub4
crossref_primary_10_1371_journal_pone_0006733
crossref_primary_10_1111_j_1467_789X_2008_00542_x
crossref_primary_10_1097_HJH_0b013e3282861fc0
crossref_primary_10_1038_s43856_023_00363_0
crossref_primary_10_1111_j_1464_5491_2011_03513_x
crossref_primary_10_1096_fj_09_147066
crossref_primary_10_1155_2010_610479
crossref_primary_10_1136_oem_2008_044917
crossref_primary_10_1002_dmrr_910
crossref_primary_10_1017_S0007114518003240
crossref_primary_10_1038_nrneph_2011_51
crossref_primary_10_1002_art_38918
crossref_primary_10_1017_S0007114509371676
crossref_primary_10_1186_1753_6561_6_S3_P28
crossref_primary_10_3390_jpm11020119
crossref_primary_10_1016_j_metabol_2012_07_009
crossref_primary_10_1097_MED_0b013e3280d5f7e9
crossref_primary_10_3109_10408363_2015_1092106
crossref_primary_10_3390_nu17030526
crossref_primary_10_1038_s41387_018_0046_9
crossref_primary_10_5694_j_1326_5377_2009_tb02317_x
crossref_primary_10_1111_j_1753_4887_2009_00181_x
crossref_primary_10_32345_USMYJ_4_134__2022_29_36
crossref_primary_10_1177_1741826711422990
crossref_primary_10_1002_dmrr_740
crossref_primary_10_1155_2017_1375342
crossref_primary_10_3390_ijms23158668
crossref_primary_10_1002_mnfr_200700030
crossref_primary_10_1007_s13668_023_00458_z
crossref_primary_10_1016_j_tem_2018_07_003
crossref_primary_10_1136_bmjopen_2018_025524
crossref_primary_10_1016_j_jcjd_2013_07_029
crossref_primary_10_1002_pdi_1359
crossref_primary_10_1007_s00125_008_1243_1
crossref_primary_10_1016_j_humimm_2017_06_001
crossref_primary_10_2337_dc08_1980
crossref_primary_10_1016_S0140_6736_06_69826_7
crossref_primary_10_1152_ajprenal_00314_2016
Cites_doi 10.2337/diabetes.53.3.693
10.1007/BF03402125
10.1191/1352458504ms1080oa
10.1002/(SICI)1520-7560(199901/02)15:1<47::AID-DMRR9>3.0.CO;2-J
10.1161/01.CIR.0000148980.87579.5E
10.1016/S0161-5890(02)00013-5
10.1073/pnas.94.9.4782
10.1007/s00125-002-0829-2
10.2337/diacare.26.12.3230
10.1161/hc0502.103331
10.2337/diabetes.51.5.1596
10.1016/S0006-291X(02)00648-4
10.1001/archinte.163.1.93
10.1161/01.CIR.0000149077.87074.DE
10.1016/S0140-6736(99)01046-6
10.1097/00041433-200410000-00009
10.1056/NEJMoa012512
10.2337/diabetes.51.4.1131
10.1001/jama.290.14.1884
10.1093/clinchem/45.12.2136
10.1056/NEJM200105033441801
10.1056/NEJM199406023302201
10.1161/01.ATV.21.6.968
10.2337/diacare.27.3.813
10.1007/s00125-005-1764-9
10.2337/diabetes.54.1.158
10.2337/diabetes.52.10.2532
10.1007/s001250051229
10.4049/jimmunol.172.7.4018
10.2337/diabetes.50.10.2384
10.1055/s-2005-858227
10.2337/diabetes.52.3.812
10.1001/jama.291.16.1978
10.1001/jama.286.3.327
10.1016/S0002-9149(00)01355-2
ContentType Journal Article
CorporateAuthor for the Finnish Diabetes Prevention Study Group
CorporateAuthor_xml – name: for the Finnish Diabetes Prevention Study Group
DBID AAYXX
CITATION
DOI 10.2337/db05-1320
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1939-327X
EndPage 2346
ExternalDocumentID 10_2337_db05_1320
diabetes_55_8_2340
GroupedDBID -
08R
0R
1AW
29F
2WC
3V.
4.4
53G
55
5GY
5RE
5RS
5VS
7RV
7X7
88E
88I
8AF
8AO
8C1
8F7
8FE
8FH
8FI
8FJ
8G5
8GL
8R4
8R5
AAQQT
AAWTL
AAYEP
AAYJJ
ABFLS
ABOCM
ABPTK
ABUWG
ACDCL
ACGOD
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AFFNX
AFKRA
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BAWUL
BBAFP
BBNVY
BCR
BCU
BEC
BENPR
BES
BHPHI
BKEYQ
BKNYI
BLC
BPHCQ
BVXVI
C1A
CS3
DIK
DU5
DWQXO
E3Z
EBS
EDB
EJD
EX3
F5P
FRP
FYUFA
GICCO
GJ
GNUQQ
GUQSH
GX1
H13
HCIFZ
HZ
IAG
IAO
IEA
IHR
INH
INR
IOF
IPO
J5H
K-O
K9-
KM
KQ8
L7B
LK8
M0R
M1P
M2O
M2P
M2Q
M5
M7P
MBDVC
O0-
O9-
OB3
OBH
OK1
OVD
P2P
PADUT
PCD
PEA
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
Q2X
RHF
RHI
RPM
S0X
SJFOW
SJN
SV3
TDI
WH7
WOQ
WOW
X7M
XZ
ZA5
ZGI
ZY1
---
.55
.GJ
.XZ
08P
0R~
18M
354
6PF
AAFWJ
AAKAS
AAYOK
AAYXX
ACGFO
ADGHP
ADZCM
AEGXH
AERZD
AIAGR
AIZAD
ALIPV
BTFSW
CCPQU
CITATION
EMOBN
HMCUK
HZ~
ITC
K2M
M5~
N4W
NAPCQ
OHH
PHGZM
PHGZT
TEORI
TR2
UKHRP
VVN
W8F
YFH
YHG
YOC
~KM
ID FETCH-LOGICAL-c2110-e9fad8030fd847b01f45ea80d8542ed424e68acb94b7485f32d740e7d9699efe3
ISSN 0012-1797
IngestDate Tue Jul 01 04:24:03 EDT 2025
Thu Apr 24 22:57:12 EDT 2025
Fri Jan 15 19:45:54 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2110-e9fad8030fd847b01f45ea80d8542ed424e68acb94b7485f32d740e7d9699efe3
OpenAccessLink https://diabetesjournals.org/diabetes/article-pdf/55/8/2340/384818/zdb00806002340.pdf
PMID 16873699
PageCount 7
ParticipantIDs crossref_primary_10_2337_db05_1320
highwire_diabetes_diabetes_55_8_2340
crossref_citationtrail_10_2337_db05_1320
ProviderPackageCode RHF
RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20060801
2006-08-01
PublicationDateYYYYMMDD 2006-08-01
PublicationDate_xml – month: 08
  year: 2006
  text: 20060801
  day: 01
PublicationDecade 2000
PublicationTitle Diabetes (New York, N.Y.)
PublicationYear 2006
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
References 2022031208461028700_R24
2022031208461028700_R23
2022031208461028700_R22
2022031208461028700_R21
2022031208461028700_R28
2022031208461028700_R27
2022031208461028700_R26
2022031208461028700_R25
2022031208461028700_R9
2022031208461028700_R20
2022031208461028700_R19
2022031208461028700_R18
2022031208461028700_R13
2022031208461028700_R35
2022031208461028700_R12
2022031208461028700_R34
2022031208461028700_R11
2022031208461028700_R33
2022031208461028700_R10
2022031208461028700_R32
2022031208461028700_R17
2022031208461028700_R16
2022031208461028700_R15
2022031208461028700_R37
2022031208461028700_R14
2022031208461028700_R36
2022031208461028700_R31
2022031208461028700_R30
2022031208461028700_R4
2022031208461028700_R3
2022031208461028700_R2
2022031208461028700_R1
2022031208461028700_R8
2022031208461028700_R7
2022031208461028700_R6
2022031208461028700_R5
2022031208461028700_R29
References_xml – ident: 2022031208461028700_R15
  doi: 10.2337/diabetes.53.3.693
– ident: 2022031208461028700_R32
  doi: 10.1007/BF03402125
– ident: 2022031208461028700_R37
  doi: 10.1191/1352458504ms1080oa
– ident: 2022031208461028700_R30
  doi: 10.1002/(SICI)1520-7560(199901/02)15:1<47::AID-DMRR9>3.0.CO;2-J
– ident: 2022031208461028700_R26
  doi: 10.1161/01.CIR.0000148980.87579.5E
– ident: 2022031208461028700_R34
  doi: 10.1016/S0161-5890(02)00013-5
– ident: 2022031208461028700_R23
– ident: 2022031208461028700_R31
  doi: 10.1073/pnas.94.9.4782
– ident: 2022031208461028700_R19
  doi: 10.1007/s00125-002-0829-2
– ident: 2022031208461028700_R5
  doi: 10.2337/diacare.26.12.3230
– ident: 2022031208461028700_R29
  doi: 10.1161/hc0502.103331
– ident: 2022031208461028700_R12
  doi: 10.2337/diabetes.51.5.1596
– ident: 2022031208461028700_R33
  doi: 10.1016/S0006-291X(02)00648-4
– ident: 2022031208461028700_R14
  doi: 10.1001/archinte.163.1.93
– ident: 2022031208461028700_R27
  doi: 10.1161/01.CIR.0000149077.87074.DE
– ident: 2022031208461028700_R8
  doi: 10.1016/S0140-6736(99)01046-6
– ident: 2022031208461028700_R35
  doi: 10.1097/00041433-200410000-00009
– ident: 2022031208461028700_R4
  doi: 10.1056/NEJMoa012512
– ident: 2022031208461028700_R11
  doi: 10.2337/diabetes.51.4.1131
– ident: 2022031208461028700_R1
  doi: 10.1001/jama.290.14.1884
– ident: 2022031208461028700_R20
  doi: 10.1093/clinchem/45.12.2136
– ident: 2022031208461028700_R3
  doi: 10.1056/NEJM200105033441801
– ident: 2022031208461028700_R18
  doi: 10.1056/NEJM199406023302201
– ident: 2022031208461028700_R28
  doi: 10.1161/01.ATV.21.6.968
– ident: 2022031208461028700_R24
  doi: 10.2337/diacare.27.3.813
– ident: 2022031208461028700_R25
  doi: 10.1007/s00125-005-1764-9
– ident: 2022031208461028700_R7
  doi: 10.2337/diabetes.54.1.158
– ident: 2022031208461028700_R6
  doi: 10.2337/diabetes.52.10.2532
– ident: 2022031208461028700_R22
– ident: 2022031208461028700_R17
  doi: 10.1007/s001250051229
– ident: 2022031208461028700_R36
  doi: 10.4049/jimmunol.172.7.4018
– ident: 2022031208461028700_R9
  doi: 10.2337/diabetes.50.10.2384
– ident: 2022031208461028700_R2
  doi: 10.1055/s-2005-858227
– ident: 2022031208461028700_R13
  doi: 10.2337/diabetes.52.3.812
– ident: 2022031208461028700_R16
  doi: 10.1001/jama.291.16.1978
– ident: 2022031208461028700_R10
  doi: 10.1001/jama.286.3.327
– ident: 2022031208461028700_R21
  doi: 10.1016/S0002-9149(00)01355-2
SSID ssj0006060
Score 1.8123935
Snippet Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes Results From the Finnish Diabetes Prevention Study Christian Herder 1 ,...
The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity, improving diet, and decreasing...
SourceID crossref
highwire
SourceType Enrichment Source
Index Database
Publisher
StartPage 2340
Title Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes
URI http://diabetes.diabetesjournals.org/content/55/8/2340.abstract
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVKJyFeEJ9iDJCFNgkJBRLbSZ1HKEMdYhNCnehbZMf2qFa1qGsfxk_gV3NvbSeh9GHwEqVpnKq5R-d-2PeYkEOW6UxxwRLOFU-EyVUCfh3buDItdQEEqLE0cHpWjM7Fp0k-6fV-dVYtrVf6Tf1zZ1_J_1gVroFdsUv2HyzbPBQuwDnYF45gYTjeyMZebnxavz7BLg-7mXVRm-1zsBz-eeqA8q9nNrQQXMU1jVG2yYeKY1-EDUtjrrrR6odOYXZ7y55OCWFklyb0E34PnNEyLu5a7akN24Iu1w3DL-x8uuGZb4uZu1DBg-I3S3U0HB5J6R3EyexSbdcmZKxNBL7NGAqgepdqPcWWvEw4G0y6HOylegPWZJdQuVdzCs4ZPha7iJ_xjXSA0airylnaerc4o7_l9JqliJAE4eAKh1Y49BbZY5BypH2y9_747MvXxq9DqucbmsJ_8jpVOPht87t_RjdRcboTsYzvkbsh1aDvPG7uk56dPyC3T8NiiodkHOFDPXxoAx8K8KENfGiAD53OKcCHtvChC0cRPpTRCJVH5Pzj8Xg4SsImG0mNuX9iS6eMBKp3BgIVnWZO5FbJ1MhcMGsEE7aQqtal0AMhc8eZGYjUDkxZlKV1lj8m_TkA6QmhNXgHa4VwOLfNixJcA6oFFqrOBNO63iev4sup6qBAjxuhzKq_jLBPXja3_vCyK7tuOoxvuIozFe1JnleyQvg8vcmzDsidFsDPSH-1XNvnEG6u9IuAg99ZPnyi
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+Immune+Mediators+and+Lifestyle+Changes+in+the+Prevention+of+Type+2+Diabetes&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Herder%2C+Christian&rft.au=Peltonen%2C+Markku&rft.au=Koenig%2C+Wolfgang&rft.au=Kra%CC%88ft%2C+Ilka&rft.date=2006-08-01&rft.issn=0012-1797&rft.eissn=1939-327X&rft.volume=55&rft.issue=8&rft.spage=2340&rft.epage=2346&rft_id=info:doi/10.2337%2Fdb05-1320&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db05_1320
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon